HIPAA vs FDA 21 CFR Part 11
HIPAA
US federal regulation for health information privacy security
FDA 21 CFR Part 11
FDA regulation for trustworthy electronic records and signatures
Quick Verdict
HIPAA protects patient health data privacy and security in healthcare, while FDA 21 CFR Part 11 ensures electronic records/signatures are trustworthy for life sciences. Organizations adopt HIPAA for compliance and trust; Part 11 for regulatory acceptance and data integrity.
HIPAA
Health Insurance Portability and Accountability Act of 1996
Key Features
- Risk-based safeguards for electronic PHI confidentiality
- Minimum necessary principle limiting PHI disclosures
- Presumption-of-breach with four-factor risk assessment
- Direct liability for business associates via BAAs
- Individual rights to access and amend PHI
FDA 21 CFR Part 11
21 CFR Part 11: Electronic Records; Electronic Signatures
Key Features
- Equivalence criteria for electronic records to paper
- Secure time-stamped audit trails for changes
- Unique multi-component electronic signatures
- Closed/open system controls with validation
- Risk-based enforcement per 2003 FDA guidance
Detailed Analysis
A comprehensive look at the specific requirements, scope, and impact of each standard.
HIPAA Details
What It Is
Health Insurance Portability and Accountability Act of 1996 (HIPAA) is a US federal regulation establishing national standards for protecting individuals' health information. It comprises Privacy Rule, Security Rule, and Breach Notification Rule, using a risk-based, flexible, scalable approach for covered entities and business associates handling protected health information (PHI) and electronic PHI (ePHI).
Key Components
- Seven pillars: scope/applicability, Privacy controls, Security safeguards (administrative/physical/technical), Breach Notification, individual rights, business associate governance, enforcement.
- Core principles: minimum necessary, TPO disclosures, de-identification methods.
- No fixed controls; requires documented risk analysis and reasonable protections enforced by OCR.
Why Organizations Use It
Mandated for healthcare providers, plans, clearinghouses; reduces breach risks, penalties (up to millions), ensures data flows for care. Builds trust, enables secure operations, differentiates in vendor ecosystems.
Implementation Overview
Phased: assess risks/gaps, build safeguards/training/BAAs, operate/monitor, assure via audits. Applies to US healthcare entities of all sizes; ongoing compliance with six-year documentation, no certification but OCR audits.
FDA 21 CFR Part 11 Details
What It Is
FDA 21 CFR Part 11 is a U.S. FDA regulation establishing criteria for electronic records and electronic signatures to be trustworthy, reliable, and equivalent to paper records and handwritten signatures. It applies to FDA-regulated industries using electronic systems for predicate-rule records. Adopts a risk-based approach per 2003 guidance, narrowing scope to relied-upon electronic records.
Key Components
- **Subpart BControls for closed (§11.10: validation, audit trails, access) and open (§11.30: encryption, digital signatures) systems; signature manifestation/linking.
- **Subpart CElectronic signatures (uniqueness, multi-component, non-repudiation).
- 11 core controls in closed systems; built on ALCOA+ principles.
- Compliance via validation, no formal certification.
Why Organizations Use It
- Mandatory for life sciences firms using electronic records/signatures.
- Mitigates enforcement risks (warnings, holds); ensures data integrity.
- Enables secure paperless operations, faster inspections, quality improvements.
- Builds regulator/partner trust.
Implementation Overview
- Risk-based scoping, CSV (GAMP5, IQ/OQ/PQ), SOPs, training.
- Phased: gap analysis, vendor assessment, validation, monitoring.
- Targets pharma/biotech/device firms; U.S.-focused audits.
Key Differences
| Aspect | HIPAA | FDA 21 CFR Part 11 |
|---|---|---|
| Scope | PHI privacy, security, breach notification | Electronic records/signatures trustworthiness |
| Industry | Healthcare providers, plans, associates | Pharma, devices, life sciences manufacturers |
| Nature | Mandatory HHS regulation with OCR enforcement | FDA regulation with enforcement discretion |
| Testing | Risk analysis, ongoing safeguards evaluation | System validation (IQ/OQ/PQ), audit trails |
| Penalties | Civil penalties up to $2M annually | Warning letters, product holds, injunctions |
Scope
Industry
Nature
Testing
Penalties
Frequently Asked Questions
Common questions about HIPAA and FDA 21 CFR Part 11
HIPAA FAQ
FDA 21 CFR Part 11 FAQ
You Might also be Interested in These Articles...

Your Compliance Command Center: How Modern Tools Orchestrate Cross-Departmental Adherence
Unlock your compliance command center with modern tools for real-time monitoring, automation & integrations across IT, HR, Legal & Finance. Slash non-compliance

Measuring CIS Controls v8.1 in the Real World: KPIs, Dashboards, and Automated Evidence for Continuous Assurance
Master CIS Controls v8.1 measurement with essential KPIs, executive-ready dashboards, and automated evidence collection for continuous assurance. Make complianc

CMMC Scoping Mastery for Defense Supply Chains: Enclave Mapping, Subcontractor Flow-Down, and CUI Inventory Blueprint
Master CMMC scoping for DIB: delineate FCI/CUI boundaries, segment enclaves, manage subcontractor flow-down. Prevent 80% assessment failures with SSP templates,
Run Maturity Assessments with GRADUM
Transform your compliance journey with our AI-powered assessment platform
Assess your organization's maturity across multiple standards and regulations including ISO 27001, DORA, NIS2, NIST, GDPR, and hundreds more. Get actionable insights and track your progress with collaborative, AI-powered evaluations.
Explore More Comparisons
See how HIPAA and FDA 21 CFR Part 11 compare against other standards